BLIS Technologies (NZSE:BLT) Altman Z2-Score: 4.93 (As of Jul. 05, 2026)


What is BLIS Technologies Altman Z2-Score?

BLIS Technologies NZSE:BLT Altman Z2-Score is 4.93 as of Jul. 05, 2026. The stock has 4 warning signs investors should review. Among 1,391 Biotechnology companies, BLIS Technologies ranks better than 71.68% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

BLIS Technologies has a Altman Z2-Score of 4.93, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for BLIS Technologies's Altman Z2-Score or its related term are showing as below:

NZSE:BLT' s Altman Z2-Score Range Over the Past 10 Years
Min: -24.42   Med: -3.17   Max: 4.93
Current: 4.93

During the past 13 years, BLIS Technologies's highest Altman Z2-Score was 4.93. The lowest was -24.42. And the median was -3.17.


BLIS Technologies  (NZSE:BLT) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


BLIS Technologies Altman Z2-Score Related Terms


BLIS Technologies Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for BLIS Technologies's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLIS Technologies Altman Z2-Score Chart

BLIS Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 0.61 4.77 3.94 4.93

BLIS Technologies Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.77 0.00 3.94 0.00 4.93

NZSE:BLT vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, BLIS Technologies's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Altman Z2-Score falls into.



BLIS Technologies Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

BLIS Technologies's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.7328+3.26*-2.2522+6.72*0.0529+1.05*6.7675
=4.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was NZ$14.97 Mil.
Total Current Assets was NZ$12.64 Mil.
Total Current Liabilities was NZ$1.67 Mil.
Retained Earnings was NZ$-33.71 Mil.
Pre-Tax Income was NZ$0.75 Mil.
Interest Expense was NZ$-0.04 Mil.
Total Liabilities was NZ$1.93 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(12.639 - 1.671)/14.968
=0.7328

X2=Retained Earnings/Total Assets
=-33.711/14.968
=-2.2522

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(0.754 - -0.038)/14.968
=0.0529

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(13.041 - 0)/1.927
=6.7675

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

BLIS Technologies has a Altman Z2-Score of 4.93 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 4.93 mean?
BLIS Technologies (NZSE:BLT) has a Altman Z2-Score of 4.93 as of Jul. 05, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on BLIS Technologies and its competitors. According to the industry distribution chart, BLIS Technologies ranks #394 out of 1391 companies in the Biotechnology industry, placing it in the top 28.3%.
Is BLIS Technologies' Altman Z2-Score too high?
BLIS Technologies' current Altman Z2-Score is 4.93. Based on the distribution chart, BLIS Technologies ranks #394 out of 1391 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #394 out of 1391 companies for Altman Z2-Score. This puts BLIS Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on BLIS Technologies and its competitors. BLIS Technologies's current Altman Z2-Score is 4.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current Altman Z2-Score is 4.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Altman Z2-Score is 4.93 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BLIS Technologies Business Description

Address 399 Moray Place, Dunedin Central, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.